Symbols

NYXH

Nyxoah·NASDAQ

--(--)

Signals Analysis

Bullish signal 3

Bearish signal 1

Consensus Rating "Strong Buy"

Revenue Beats Expectation

EPS Beats Expectation

Bearish Abandoned Baby

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About NYXH

Nyxoah Sa

A medical technology company focused on developing and commercializing innovative solutions for the treatment of obstructive sleep apnea (OSA)

Industry

Healthcare Equipment and Supplies

Established Date

07/15/2009

Listing Date

07/02/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

184

Fiscal Year Ends

12-31

Website

www.nyxoah.com

Security Type

Common stock

Office address

Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium

Business

Introduction

Nyxoah SA was incorporated in Belgium on July 15, 2009. The company is a medical technology company focused on the development and commercialization of innovative solutions for the treatment of obstructive sleep apnea (OSA), and its lead product is the Genio system. This CE certified product is a patient-centered, minimally invasive next-generation hypoglossal nerve stimulation (HGNS) therapy for the treatment of moderate to severe OSA. OSA is a common sleep-disordered breathing disorder worldwide and is associated with a higher risk of death and a variety of complications including cardiovascular disease, depression and stroke. The company's innovative technology platform is the first HGNS device to treat OSA through bilateral stimulation, designed to maintain the airway open, thereby ensuring that patients get a peaceful sleep. Nyxoah SA, which began selling the Genio system in Europe in July 2020 and is generating revenue, is currently conducting DREAM pivotal trials to support its marketing authorization application in the United States.

Company Financials

EPS

NYXH has released its 2025 Q3 earnings. EPS was reported at -0.73, versus the expected -0.68, missing expectations. The chart below visualizes how NYXH has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

NYXH has released its 2025 Q3 earnings report, with revenue of 2.31M, reflecting a YoY change of 64.01%, and net profit of -27.67M, showing a YoY change of -45.55%. The Sankey diagram below clearly presents NYXH's revenue sources and cost distribution.